This description is a summary of our understanding of the job description. Click on 'Apply' button to find out more.

Role Description

Ultragenyx is preparing for the potential commercialization of a rare disease Antisense oligonucleotide therapy for the treatment of Angelman Syndrome. We are seeking a highly analytical, collaborative MBA Intern to support global launch readiness with a specific focus on Phase 3 (Ph3) data-driven scenario planning. This role will help design and execute workstreams and trigger-based plans that activate when Ph3 data become available.

• Build a scenario framework for anticipated Ph3 readouts (primary/secondary endpoint outcomes, safety profile ranges, subpopulation signals, sensitivity analyses).
• Work with the cross-functional team to design decision trees and activation triggers linked to each scenario, mapping implications for updating all global materials.
• Define insight needs (ad boards, message testing, ATUs, discrete choice/TPP trade-offs, analog analysis) triggered by each scenario.
• Recommend governance cadence (war room / stand-ups, escalation paths, decision logs) for the 0–90 days post-readout window.

Qualifications

• Current MBA student (rising 2nd year or equivalent) with a focus in Marketing, Strategy, Healthcare Management, or Finance.
• 2–3+ years pre-MBA experience in biopharma, life sciences consulting, healthcare investing/analytics, or related.
• Strong strategic thinking and structured problem solving; comfort with ambiguity and scenario-based planning.
• Excellent communication and stakeholder management skills.

Requirements

• Optional experience in neurology, CNS, or rare/orphan diseases, or early/first launch environments.

Benefits

• Generous vacation time and public holidays observed by the company.
• Volunteer days.
• Long term incentive and Employee stock purchase plans or equivalent offerings.
• Employee wellbeing benefits.
• Fitness reimbursement.
• Tuition sponsoring.
• Professional development plans.
• * Benefits vary by region and country.